1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Hepatomegaly: new trials by email Literature Review of Hepatomegaly trials Research Report on Hepatomegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment - Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2015-05-14 | 2019-05-15 |
Polycythemia Vera (1) · Primary Myelofibrosis (1) · Splenomegaly (1)
Bone Marrow Diseases (1) · Bone Marrow Neoplasms (1) · Digestive System Diseases (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hemic and Lymphatic Diseases (1) · Hypertrophy (1) · Liver Diseases (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
Nivolumab (1)
M.D. Anderson Cancer Center (1)
United States (1)
Srdan Verstovsek (1)
P30CA016672 (1)